Clinical Edge Journal Scan

Vacuum-assisted biopsy predicts post-treatment residual disease in breast cancer


 

Key clinical point : Vacuum-assisted biopsy accurately predicted residual disease in breast cancer patients after neoadjuvant chemotherapy.

Major finding: The overall false negative rate using vacuum-assisted biopsy (VAB) was 18.7%; in a subgroup of patients with a complete/partial response and imaging abnormalities of 2 cm or smaller, the false negative rate was 3.2% and the negative predictive value was 97.4% for an overall accuracy of 89.5% with VAB.

Study details : The data come from a diagnostic study of 166 women with breast cancer who received neoadjuvant chemotherapy followed by image-guided biopsy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Citation: Tasoulis MK et al. JAMA Surg. 2020 Oct 7. doi: 10.1001/jamasurg.2020.4103.

Recommended Reading

New estimates for breast cancer risk with HRT
MDedge Hematology and Oncology
One-month delay in cancer treatment linked to increase in mortality
MDedge Hematology and Oncology
Study supports genetic testing in older women with breast cancer
MDedge Hematology and Oncology
New cancer drugs may have saved more than 1.2 million Americans
MDedge Hematology and Oncology
‘Test all patients with cancer’: One in eight have inherited mutations
MDedge Hematology and Oncology
Pembrolizumab approved for triple-negative breast cancer
MDedge Hematology and Oncology
Using telehealth to deliver palliative care to cancer patients
MDedge Hematology and Oncology
Pregnancy outcomes ‘favorable’ after BRCA breast cancer treatment
MDedge Hematology and Oncology
Black women show higher rates of three breast cancer subtypes
MDedge Hematology and Oncology
Immediate breast reconstruction after chemotherapy doesn’t hurt survival
MDedge Hematology and Oncology